Clinical Trial

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
Protocol Amendment History 33 amendments
This ClinicalTrials.gov record has been amended 33 times since 2022-11-23; most recent amendment 2026-04-14.
Status change: Recruiting → Active, Not Recruiting 2025-01-14
Status change: Not Yet Recruiting → Recruiting 2023-05-22
Trial Details
NCT Number NCT05635708
Lead Sponsor BeiGene
Conditions Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Enrollment 400 participants
Start Date 2023-03-07
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-15